Davidson Jacob B, Edakkanambeth Varayil Jithinraj, Okano Akiko, Whitaker Jennifer A, Bonnes Sara L, Kelly Darlene G, Mundi Manpreet S, Hurt Ryan T
1 Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota.
2 Department of Family and Community Medicine, University of Illinois College of Medicine at Rockford, Rockford, Illinois.
JPEN J Parenter Enteral Nutr. 2017 May;41(4):685-690. doi: 10.1177/0148607115604118. Epub 2015 Sep 2.
Catheter-related bloodstream infection (CRBSI) is a serious complication in patients receiving home parenteral nutrition (HPN). Antibiotic lock therapy (ALT) and ethanol lock therapy (ELT) can be used to prevent CRBSI episodes in high-risk patients.
Following institutional review board approval, all patients enrolled in the Mayo Clinic HPN program from January 1, 2006, to December 31, 2013, with catheter locking were eligible to be included. Patients without research authorization and <18 years old at the initiation of HPN were excluded. Total number of infections before and after ALT or ELT were estimated in all patients.
A total of 63 patients were enrolled during the study period. Of 59 eligible patients, 29 (49%) were female, and 30 (51%) were male. The median duration of HPN was 3.66 (interquartile range, 0.75-8.19) years. The mean age ± SD at initiation of HPN was 49.89 ± 14.07 years. A total of 51 patients were instilled with ALT, and 8 patients were instilled with ELT during their course of HPN. A total of 313 CRBSI episodes occurred in these patients, 264 before locking and 49 after locking ( P < .001). Rate of infection per 1000 catheter days was 10.97 ± 25.92 before locking and 1.09 ± 2.53 after locking ( P < .001).
The major findings of the present study reveal that ALT or ELT can reduce the overall rate of infections per 1000 catheter days. ALT or ELT can be used in appropriate clinical setting for patients receiving HPN.
导管相关血流感染(CRBSI)是接受家庭肠外营养(HPN)患者的一种严重并发症。抗生素封管疗法(ALT)和乙醇封管疗法(ELT)可用于预防高危患者发生CRBSI。
经机构审查委员会批准,2006年1月1日至2013年12月31日期间纳入梅奥诊所HPN项目且进行导管封管的所有患者均符合纳入条件。排除未获得研究授权以及HPN开始时年龄<18岁的患者。估算所有患者在ALT或ELT治疗前后的感染总数。
研究期间共纳入63例患者。在59例符合条件的患者中,29例(49%)为女性,30例(51%)为男性。HPN的中位持续时间为3.66年(四分位间距,0.75 - 8.19年)。HPN开始时的平均年龄±标准差为49.89±14.07岁。在HPN治疗过程中,共有51例患者接受了ALT封管,8例患者接受了ELT封管。这些患者共发生313次CRBSI,封管前264次,封管后49次(P <.001)。每1000导管日的感染率在封管前为10.97±25.92,封管后为1.09±2.53(P <.001)。
本研究的主要发现表明,ALT或ELT可降低每1000导管日的总体感染率。ALT或ELT可在适当的临床环境中用于接受HPN的患者。